Evaluation by (99m)Tc-pertechnetate scintigraphy of the effect of levocetirizine on salivary glands function, in allergic rhinitis patients.
The purpose of this study was to assess the effect of levocetirizine (xyzal) on salivary glands function in patients with allergic rhinitis using technetium-99m pertechnetate ((99m)Tc-P) salivary gland scintigraphy. The study population consisted of 67 patients with allergic rhinitis and 31 healthy controls (14 males and 17 females, mean age 30.1+/-6.8 years). The patients were divided into two groups: an untreated patient Group of 32 patients, 17 males and 15 females, mean age 29.9+/-6.5 years and a levocetirizine-treated with 5mg.day(-1) for 4 weeks patient Group, consisted of 35 patients, 16 males and 19 females, mean age 33.5+/-7.8 years. All patients and healthy controls underwent salivary glands scintigraphy. After the intravenous administration of 185 MBq of (99m)Tc-P, dynamic salivary glands scintigraphy was performed for 25 min. By the time-activity curves, the following glandular function parameters were calculated for the parotid and submandibular salivary glands: uptake ratio, maximum accumulation, and ejection fraction. Our results showed: All functional parameters obtained for the untreated patient Group were significantly lower than for the levocetirizine-treated patient Group and healthy controls (P<0.05). There was no significant difference in any functional parameters between the levocetirizine-treated patient Group and healthy controls (P>0.05). In conclusion, results of our study indicate that patients with allergic rhinitis treated with levocetirizine showed a significantly higher salivary glands function compared with untreated patients and healthy controls. Levocetirizine treatment showed no side effects on salivary glands function.
Seven
Bedri
B
Department of Nuclear Medicine, Ataturk University, Medical School, 25240 Erzurum, Turkey. bedriseven@yahoo.com
Yoruk
Ozgur
O
Varoglu
Erhan
E
Ucuncu
Harun
H
Sahin
Ali
A
Kursad Ayan
Arif
A
Sutbeyaz
Yavuz
Y
D000328:Adult; D017332:Cetirizine / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D006255:Rhinitis, Allergic, Seasonal / Q000150:complications / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D012469:Salivary Glands / Q000187:drug effects; D013670:Sodium Pertechnetate Tc 99m; D016896:Treatment Outcome; D014987:Xerostomia / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D055815:Young Adult
D039563:Histamine H1 Antagonists, Non-Sedating; D019275:Radiopharmaceuticals; C472067:levocetirizine; D013670:Sodium Pertechnetate Tc 99m; D017332:Cetirizine